Search The Medical Knowledge Base
Drug Details
LASILACTONE
- Drug Class Description
Loop diuretics / K+-sparing diuretics (potassium-sparing diuretics). - Generic Name
Frusemide (furosemide), spironolactone - Presentation
Capsule. - Description
Lasilactone contains 20mg Furosemide and 50mg Spironolactone - Indications
Lasilactone contains a short-acting diuretic and a long-acting aldosterone antagonist. It is indicated in the treatment of resistant oedema where this is associated with secondary hyperaldosteronism; conditions include chronic congestive cardiac failure and hepatic cirrhosis. Treatment with Lasilactone should be reserved for cases refractory to a diuretic alone at conventional doses.
This fixed ratio combination should only be used if titration with the component drugs separately indicates that this product is appropriate. The use of Lasilactone in the management of essential hypertension should be restricted to patients with demonstrated hyperaldosteronism. It is recommended that in these patients also, this combination should only be used if titration with the component drugs separately indicates that this product is appropriate.
- Adult Dosage
For oral administration.
Adults: 1-4 capsules daily.
Children: The product is not suitable for use in children.
Elderly: Furosemide and Spironolactone may both be excreted more slowly in the elderly.
The capsules should be swallowed whole. They are best taken at breakfast and/or lunch with a generous amount of liquid (approx. 1 glass). An evening dose is not recommended, especially during initial treatment, because of the increased nocturnal output of urine to be expected in such cases.
- Child Dosage
Not recommended. - Contra Indications
Patients with hypovolaemia or dehydration (with or without accompanying hypotension). Patients with an impaired renal function and a creatinine clearance below 30ml/min per 1.73 m2 body surface area, anuria or renal failure with anuria not responding to furosemide, renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents or renal failure associated with hepatic coma, hyperkalaemia, severe hypokalaemia, severe hyponatraemia, Addison's disease and breast feeding women.
Hypersensitivity to furosemide, spironolactone, sulphonamides or sulphonamide derivatives, or any of the excipients of Lasilactone.
- Special Precautions
Spironolactone may cause vocal changes. In determining whether to initiate treatment with Lasilactone, special attention must be given to this possibility in patients whose voice is particularly important for their work (e.g., actors, singers, teachers).
Urinary output must be secured. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition have an increased risk of developing acute retention and require careful monitoring.
Where indicated, steps should be taken to correct hypotension or hypovolaemia before commencing therapy.
Particularly careful monitoring is necessary in:
• patients with hypotension.
• patients who are at risk from a pronounced fall in blood pressure.
• patients where latent diabetes may become manifest or the insulin requirements of diabetic patients may increase.
• patients with gout.
• patients with hepatic cirrhosis together with impaired renal function.
• patients with hypoproteinaemia, e.g. associated with nephrotic syndrome (the effect of furosemide may be weakened and its ototoxicity potentiated). Cautious dose titration is required.
Administration of Lasilactone should be avoided in the presence of a raised serum potassium. Concomitant administration of triamterene, amiloride, potassium supplements or non-steroidal anti-inflammatory drugs is not recommended as hyperkalaemia may result.
Caution should be observed in patients liable to electrolyte deficiency. Regular monitoring of serum sodium, potassium, creatinine and glucose is generally recommended during therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss. Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Lasilactone.
Frequent checks of the serum potassium level are necessary in patients with impaired renal function and a creatinine clearance below 60ml/min per 1.73m2 body surface area as well as in cases where Lasilactone is taken in combination with certain other drugs which may lead to an increase in potassium levels.
In patients who are at high risk for radiocontrast nephropathy, furosemide is not recommended to be used for diuresis as part of the preventative measures against radiocontrast-induced nephropathy.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
- Interactions
The dosage of concurrently administered cardiac glycosides, diuretics, anti-hypertensive agents, or other drugs with blood-pressure-lowering potential may require adjustment as a more pronounced fall in blood pressure must be anticipated if given concomitantly with Lasilactone. A marked fall in blood pressure and deterioration in renal function may be seen when ACE inhibitors or angiotensin II receptor antagonists are added to furosemide therapy, or their dose level increased. The dose of Lasilactone should be reduced for at least three days, or the drug stopped, before initiating the ACE inhibitor or angiotensin II receptor antagonist or increasing their dose.
When Lasilactone is taken in combination with potassium salts, with drugs which reduce potassium excretion, with non-steroidal anti-inflammatory drugs or with ACE inhibitors, an increase in serum potassium concentration and hyperkalaemia may occur.
The toxic effects of nephrotoxic drugs may be increased by concomitant administration of potent diuretics such as furosemide.
Lasilactone and sucralfate must not be taken within two hours of each other because sucralfate decreases the absorption of furosemide from the intestine and so reduced its effect.
In common with other diuretics, serum lithium levels may be increased when lithium is given concomitantly with Lasilactone, resulting in increased lithium toxicity, including increased risk of cardiotoxic and neurotoxic effects of lithium. Therefore, it is recommended that lithium levels are carefully monitored and where necessary the lithium dosage is adjusted in patients receiving this combination.
Certain non-steroidal anti-inflammatory agents (e.g.indometacin, acetylsalicylic acid) may attenuate the action of Lasilactone and may cause acute renal failure in cases of pre-existing hypovolaemia or dehydration.
Salicylic toxicity may be increased by Lasilactone. Lasilactone may sometimes attenuate the effects of other drugs (e.g. the effects of antidiabetics and pressor amines) and sometimes potentiate them (e.g. the effects of salicylates, theophylline and curare-type muscle relaxants).
Lasilactone may potentiate the ototoxicity of aminoglycosides and other ototoxic drugs. Since this may lead to irreversible damage, these drugs must only be used with Lasilactone if there are compelling medical reasons.
There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly. In addition, nephrotoxicity of cisplatin may be enhanced if furosemide is not given in low doses (e.g. 40 mg in patients with normal renal function) and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.
Spironolactone may cause raised digoxin levels. Some electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia) may increase the toxicity of certain other drugs (e.g. digitalis preparations and drugs inducing QT interval prolongation syndrome).
Attenuation of the effect of Lasilactone may occur following concurrent administration of phenytoin.
Concomitant administration of carbamazepine or aminoglutethimide may increase the risk of hyponatraemia.
Corticosteroids administered concurrently may cause sodium retention.
Both spironolactone and carbenoloxone may impair the action of the other substance. In this regard, liquorice in larger amounts acts in a similar manner to carbenoxolone. Corticosteroids, carbenoxolone, liquorice, B2 sympathomimetics in large amounts, and prolonged use of laxatives, reboxetine and amphotericin may increase the risk of developing hypokalaemia.
Probenecid, methotrexate and other drugs which, like furosemide, undergo significant renal tubular secretion may reduce the effect of Lasilactone. Conversely, furosemide may decrease renal elimination of these drugs. In case of high-dose treatment (in particular, of both furosemide and the other drugs), this may lead to increased serum levels and an increased risk of adverse effects due to furosemide or the concomitant medication.
Impairment of renal function may develop in patients receiving concurrent treatment with furosemide and high doses of certain cephalosporins.
Concomitant use of ciclosporin and furosemide is associated with increased risk of gouty arthritis.
- Adverse Drug Reactions
Furosemide is generally well tolerated.
Bone marrow depression has been reported as a rare complication and necessitates withdrawal of treatment.
Occasionally, thrombocytopenia may occur. In rare cases, leucopenia and, in isolated cases, agranulocytosis, aplastic anaemia or haemolytic anaemia may develop. Eosinophilia is rare.
Rarely, paraesthesiae may occur.
Hepatic encephalopathy in patients with hepatocellular insufficiency may occur.
Serum calcium levels may be reduced; in very rare cases tetany has been observed. Nephrocalcinosis / Nephrolithiasis has been reported in premature infants.
Serum cholesterol and triglyceride levels may rise during furosemide treatment. During long-term therapy they will usually return to normal within six months.
Glucose tolerance may decrease with furosemide. In patients with diabetes mellitus this may lead to a deterioration of metabolic control; latent diabetes mellitus may become manifest.
Hearing disorders and tinnitus, although usually transitory, may occur in rare cases, particularly in patients with renal failure, hypoproteinaemia (e.g. in nephrotic syndrome) and/or when intravenous furosemide has been given too rapidly.
Furosemide may cause a reduction in blood pressure which, if pronounced may cause signs and symptoms such as impairment of concentration and reactions, light-headedness, sensations of pressure in the head, headache, dizziness, drowsiness, weakness, disorders of vision, dry mouth, orthostatic intolerance.
In isolated cases, intrahepatic cholestasis, an increase in liver transaminases or acute pancreatitis may develop.
The incidence of allergic reactions, such as skin rashes, photosensitivity, vasculitis, fever or interstitial nephritis, is very low, but when these occur treatment should be withdrawn. Skin and mucous membrane reactions may occasionally occur, e.g. itching, urticaria, other rashes or bullous lesions, erythema multiforme, bullous pemphigoid, exfoliative dermatitis, purpura.
As with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis after prolonged therapy.
Furosemide leads to increased excretion of sodium and chloride and consequently water. In addition excretion of other electrolytes (in particular, calcium and magnesium) is increased. The two active ingredients exert opposing influences on potassium excretion. The serum potassium concentration may decrease, especially at the commencement of treatment (owing to the earlier onset of action of furosemide), although particularly as treatment is continued, the potassium concentration may increase (owing to the later onset of action of spironolactone), especially in patients with renal failure.
Symptomatic electrolyte disturbances and metabolic alkalosis may develop in the form of a gradually increasing electrolyte deficit or, e.g. where higher furosemide doses are administered to patients with normal renal function, acute severe electrolyte losses. Warning signs of electrolyte disturbances include increased thirst, headache, hypotension, confusion, muscle cramps, tetany, muscle weakness, disorders of cardiac rhythm and gastrointestinal symptoms. In the event of an irregular pulse, tiredness or muscle weakness (e.g., in the legs), particular consideration must be given to the possibility of hyperkalaemia. Pre-existing metabolic alkalosis (e.g. in decompensated cirrhosis of the liver) may be aggravated by furosemide treatment.
Disturbances in electrolyte balance, particularly if pronounced, must be corrected.
The diuretic action may lead to or contribute to hypovolaemia and dehydration, especially in elderly patients. To avert these, it is important to compensate any undesired losses of fluid (e.g., due to vomiting or diarrhoea, or to intense sweating). Severe fluid depletion may lead to haemoconcentration with a tendency for thromboses to develop.
Increased production of urine may provoke or aggravate complaints in patients with an obstruction of urinary outflow. Thus, acute retention of urine with possible secondary complications may occur for example, in patients with bladder-emptying disorders, prostatic hyperplasia or narrowing of the urethra.
If furosemide is administered to premature infants during the first weeks of life, it may increase the risk of persistence of patent ductus arteriosus.
Severe anaphylactic or anaphylactoid reactions (e.g. with shock) occur rarely.
Side-effects of a minor nature such as nausea, malaise or gastric upset (vomiting or diarrhoea) may occur but are not usually severe enough to necessitate withdrawal of treatment.
As with other diuretics, treatment with furosemide may lead to transitory increases in blood creatinine and urea levels. Serum levels of uric acid may increase and attacks of gout may occur.
Spironolactone has been reported to induce gastrointestinal intolerance. Stomach ulcers (sometimes with bleeding) have been reported rarely. Spironolactone may also cause drowsiness, headache, ataxia and mental confusion.
Because of its chemical similarity to the sex hormones, spironolactone may make the nipples more sensitive to touch. Dose dependent mastodynia and reversible gynaecomastia may occur in both sexes. Maculopapular or erythematous cutaneous eruptions have been reported rarely, as have mild androgenic manifestation such as hirsutism and menstrual irregularities. In men, potency may occasionally be impaired. Rarely, spironolactone may cause vocal changes in the form of hoarseness and (in women), deepening of the voice or (in men) increase in pitch. In some patients these vocal changes persist even after Lasilactone has been discontinued.